Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 213-219 , November 2009

Dose-escalation using intensity-modulated radiotherapy for prostate cancer – Evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost

  • Michael Pinkawa

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany.
    • ,
  • Charbel Attieh

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Marc D. Piroth

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Richard Holy

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Sandra Nussen

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Jens Klotz

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Robert Hawickhorst

      Affiliations

    • Department of Nuclear Medicine, RWTH Aachen University, Aachen, Germany
    • ,
  • Wolfgang Schäfer

      Affiliations

    • Department of Nuclear Medicine, RWTH Aachen University, Aachen, Germany
    • ,
  • Michael J. Eble

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany

Received 12 March 2009 ,Revised 24 July 2009 ,Accepted 25 July 2009.

References 

  1. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988
  2. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  3. Zietman AL, DeSilvio M, Slater JD, et al. Comparison of conventional-dose vs. high-dose radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005;294:1233–1239
  4. Pinkawa M, Pursch-Lee M, Asadpour B, et al. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intra-fraction motion. Strahlenther Onkol. 2008;184:679–685
  5. McNair HA, Hansen VN, Parker CC, et al. A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:41–50
  6. Lee CT, Dong L, Ahamad AW, et al. Comparison of treatment volumes and techniques in prostate cancer radiation therapy. Am J Clin Oncol. 2005;28:618–625
  7. De Meerleer GO, Vakaet L, Gersem W, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000;47:639–648
  8. Vitolo V, Millender L, Quivey JM, et al. Assessment of carotid artery dose in the treatment of nasopharyngeal cancer with IMRT versus conventional radiotherapy. Radiother Oncol. 2009;90:213–220
  9. Wang J, Bai S, Chen N, et al. The clinical feasibility of online cone beam computer tomography-guided intensity-modulated radiotherapy for nasopharyngeal cancer. Radiother Oncol. 2009;90:221–227
  10. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53:595–599
  11. Chen ME, Johnston DA, Tang K, et al. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89:1800–1809
  12. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642–1649
  13. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262–269
  14. Kwee SA, Thibault GP, Stack RS, et al. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer. Mol Imaging. 2008;7:12–20
  15. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47:1249–1254
  16. Yamaguchi T, Lee J, Uemura H, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742–748
  17. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging – correlation with pathologic findings. Radiology. 2008;246:480–488
  18. Villeirs GM, Verstraete KL, De Neve WJ, et al. Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapists. Radiother Oncol. 2005;76:99–106
  19. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463–1468
  20. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1013–1015
  21. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy. Report 50, Bethesda, MD: ICRU; 1993.
  22. Yaparpalvi R, Hong L, Mah D, et al. ICRU reference dose in an era of intensity-modulated radiation therapy clinical trials: correlation with planning target volume mean dose and suitability for intensity-modulated radiation therapy dose prescription. Radiother Oncol. 2009;89:347–352
  23. Lawton CAF, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383–387
  24. Wu Q, Mohan R, Niemierko A, et al. Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys. 2002;52:224–235
  25. Dunscombe PB, Iftody S, Ploquin N, et al. The equivalent uniform dose as a severity metric for radiation treatment incidents. Radiother Oncol. 2007;84:64–66
  26. Emami B, Lyman JT, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  27. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135
  28. Rancati T, Fiorino C, Gagliardi G, et al. Fitting late rectal data using different NTCP models: results from an Italian multi-centri study (AIROPROSO101). Radiother Oncol. 2004;73:21–32
  29. McBride WH, Withers HR. Biological basis of radiation therapy. In:  Halperin EC,  Perez CA,  Brady LW editor. Principles and practice in radiation oncology. 5th ed.. Philadelphia: Lippincott Williams & Wilkins; 2007;p. 76–108
  30. De Meerleer G, Villeirs G, Bral S, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75:325–333
  31. van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303
  32. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–1434
  33. Sutinen E, Nurmi M, Roivainen A, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31:317–324
  34. Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72:799–807
  35. Bolla M, Van PH, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  36. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329–2335
  37. King CR, Kapp DS, King CR, et al. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys. 2008;71:346–350
  38. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10years. Int J Radiat Oncol Biol Phys. 2000;48:369–375

PII: S0167-8140(09)00432-0

doi: 10.1016/j.radonc.2009.07.014

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 213-219 , November 2009

Article Tools

* Image Usage & Resolution